Electroporation of synthetic oligodeoxynucleotides: A novel technique for ex vivo bone marrow purging

Blood

Volumn 88, Issue 2, 1996, Pages 731-741

  Bergan, Raymond ^a   Hakim, Frances ^a   Schwartz, Gretchen N ^a   Kyle, Edward ^a   Cepada, Rose ^a   Szabo, Janet M ^a   Fowler, Daniel ^a   Gress, Ronald ^a   Neckers, Len ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OLIGODEOXYNUCLEOTIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW PURGING; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CONTROLLED STUDY; EWING SARCOMA; HEMATOPOIESIS; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0030001042     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v88.2.731.bloodjournal882731     Document Type: Article

References (51)

1. Vesole DH, Jagannath S, Glenn L, Barlogie B: Autotransplantation in multiple myeloma. Hematol Oncol Clin North Am 7:613, 1993
2. Petersen FB, Appelbaum FR, Hill R, Fisher LD, Bigelow CL, Sanders JE, Sullivan KM, Bensinger WI, Witherspoon RP, Storb R, Clift RA, Fefer A, Press OW, Weiden PL, Singer J, Thomas ED, Buckner CD: Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle. J Clin Oncol 8:638, 1990
3. Kantarjian HM, Talpaz M, LeMaistre CF, Spinolo J, Spitzer G, Yau J, Dicke K, Jagannath S, Deisseroth AB: Intensive combination chemotherapy and autologous bone marrow transplantation leads to the reappearance of Philadelphia chromosome-negative cells in chronic myelogenous leukemia. Cancer 67:2959, 1991
4. Dicke KA, Zander AR, Spitzer G, Verma DS, Peters LJ, Vellekoop L, Thomson S, Stewart D, Hester JP, McCredie KB: Autologous bone marrow transplantation in relapsed adult acute leukemia. Exp Hematol 7:170, 1979
5. Deisseroth AB, Zu Z, Claxton D, Hanania EG, Fu S, Ellerson D, Goldberg L, Thomas M, Janicek K, Anderson WF, Hester J, Korbling M, Durett A, Moen R, Berenson R, Heimfeld S, Hamer J, Calvert L, Tibbits P, Talpaz M, Kantarjian H, Champlin R, Reading C: Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 83:3068, 1994
6. Brenner MK, Rill DR, Moen RC, Krance RA, Mirro JJ, Anderson WF, Ihle JN: Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 341:85, 1993
7. Rill DR, Santana VM, Roberts WM, Nilson T, Bowman LC, Krance RA, Heslop HE, Moen RC, Ihle JN, Brenner MK: Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 84:380, 1994
8. Jones RJ: Purging with 4-hydroperoxycyclophosphamide. J Hematother 1:343, 1992
9. Laporte JP, Douay L, Lopez M, Labopin M, Jouet JP, Lesage S, Stachowiak J, Fouillard L, Isnard F, Noel-Walter MP, Pene F, Deloux J, Van Den Akker J, Grande M, Bauters F, Najman A, Gorin NC: One hundred twenty-five adult patients with primary acute leukemia autografted with marrow purged by mafosfamide: A 10-year single institution experience. Blood 84:3810, 1994
10. Albin N, Douay L, Fouillard L, Laporte JP, Isnard F, Lesage S, Ozsahin H, Bardinet D, Najman A, Gorin NC: In vivo effects of GM-CSF and IL-3 on hematopoietic cell recovery in bone marrow and blood after autologous transplantation with mafosfamide-purged marrow in lymphoid malignancies. Bone Marrow Transplant 14:253, 1994
11. Petersen FB, Lynch MH, Clift RA, Appelbaum FR, Sanders JE, Bensinger WI, Benyunes MC, Doney K, Fefer A, Martin P, Storb R, Rowley S, Sullivan KM, Witherspoon R, Weiden P, Thomas ED, Fisher L, Hansen JA, Buchner CD: Autologous marrow transplantation for patients with acute myeloid leukemia in untreated first relapse or in second complete remission. J Clin Oncol 11:1353, 1993
12. Neame PB, Soamboonsrup P, Quigley JG, Pewarchuck W: The use of monoclonal antibodies and immune markers in the diagnosis, prognosis, and therapy of acute leukemia. Transfus Med Rev 8:59, 1994
13. de Fabritiis P, Amadori S, Calabretta B, Mandelli F: Elimination of clonogenic Philadelphia-positive cells using BCR-ABL antisense oligodeoxynucleotides. Bone Marrow Transplant 12:261, 1993
14. Neckers L, Whitesell L, Rosolen A, Geselowitz DA: Antisense inhibition of oncogene expression. Crit Rev Oncog 3:175, 1992
15. Pierga JY, Magdelenat H: Applications of antisense oligonucleotides in oncology. Cell Mol Biol 40:237, 1994
16. Pilowsky PM, Suzuki S, Minson JB: ANTISENSE oligonucleotides: A new tool in neuroscience. Clin Exp Pharmacol Physiol 21:935, 1994
17. McManaway ME, Neckers LM, Loke SL, Al-Nasser AA, Redner RL, Shiramizu BT, Goldschmidts WL, Huber BE, Bhatia K, Magrath IT: Tumourspecific inhibition of lymphoma growth by an antisense oligodeoxynucleotide. Lancet 335:808, 1990
18. Gewirtz AM: Oligodeoxynucleotide-based therapeutics for human leukemias. Stem Cells 11:96, 1993
19. Bergan R, Connell Y, Fahmy B, Neckers L: Electroporation enhances c-myc antisense oligodeoxynucleotide efficacy. Nucleic Acids Res 21:3567, 1993
20. Bayever E, Iversen PL, Bishop MR, Sharp JG, Tewary HK, Arneson MA, Pirruccello SJ, Ruddon RW, Kessinger A, Zon G, Armitage JO: Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: Initial results of a phase 1 trial. Antisense Res Dev 3:383, 1993
21. Bergan RC, Kyle E, Connell Y, Neckers L: Inhibition of protein-tyrosine kinase activity in intact cells by the aptameric action of oligodeoxynucleotides. Antisense Res Dev 5:33, 1995
22. Chang DC, Chassy BM, Saunders JA, Sowers AE: Guide to Electroporation and Electroperfusion. New York, NY, Academic, 1992
23. Toneguzzo F, Keating A: Stable expression of selectable genes introduced into human hematopoietic stem cells by electric field-mediated DNA transfer. Proc Natl Acad Sci USA 83:3496, 1986
24. Keating A, Toneguzzo F: Gene transfer by electroporation: A model for gene therapy. Prog Clin Biol Res 333:491, 1990
25. Narayanan R, Jastreboff MM, Chiu CF, Bertino JR: In vivo expression of a nonselected gene transferred into murine hematopoietic stem cells by electroporation. Biochem Biophys Res Commun 141:1018, 1986
26. Hodgson GS, Bradley TR: Properties of haematopoietic stem cells surviving 5-fluorouracil treatment: Evidence for a pre-CFU-S cell? Nature 281:381, 1979
27. Lerner C, Harrison DE: 5-Fluorouracil spares hemopoietic stem cells responsible for long term repopulation. Exp Hematol 18:114, 1990
28. Schwartz GN: Use of gel-well culture chambers as a liquid culture system to measure responses of hematopoietic colony-forming cells to growth factors. Int J Cell Cloning 7:360, 1989
29. Eaves CJ, Eaves AC: Diagnostic and therapeutic implications of the growth of hematopoietic progenitor cells in vitro, in Brain MC, Carbone PP (eds): Current Therapy in Hematology-Oncology. Philadelphia, PA, Decker, 1992, p 159
30. Harrison DE, Jordan CT, Zhong RK, Astle CM: Primitive hemopoietic stem cells: Direct assay of most productive populations by competitive repopulation with simple binomial, correlation and covariance calculations. Exp Hematol 21:296, 1993
31. Watson PH, Pon RT, Shiu RPC: Inhibition of c-myc expression by phosphorothioate antisense oligonucleotide identifies a critical role for c-cyc in the growth of human breast cancer. Cancer Res 51:3996, 1991
32. Ogawa M, Shih JP, Katayama N: Enrichment for primitive hemopoietic progenitors of marrow cells from 5-fluorouracil-treated mice and normal mice. Blood Cells 20:7, 1994
33. Nagel KM, Holstad SG, Isenberg KE: Oligonucleotide pharmacotherapy: An antigene strategy. Pharmacotherapy 13:177, 1993
34. Lefebvre d'Hellencourt C, Diaw L, Guenounou M: Immunomodulation by cytokine antisense oligonucleotides. Eur Cytokine Netw 6:7, 1995
35. Neckers LM: Cellular internalization of oligonucleotides, in Crooke ST, Lebleu B (eds): Antisense Research and Applications. Boca Raton, FL, CRC, 1993, p 451
36. Loke SL, Stein CA, Zhang XH, Mori K, Nakanishi M, Subasinghe C, Cohen JS, Neckers LM: Characterization of oligonucleotide transport into living cells. Proc Natl Acad Sci USA 86:3474, 1989
37. Yakubov LA, Deeva EA, Zarytova VF, Ivanova EM, Ryte AS, Yurchenko LV, Vlassov VV: Mechanism of oligonucleotide uptake by cells: Involvement of specific receptors? Proc Natl Acad Sci USA 86:6454, 1989
38. Gao WY, Storm C, Egan W, Cheng YC: Cellular pharmacology of phosphorothioate homooligodeoxynucleotides in human cells. Mol Pharmacol 43:45, 1993
39. Beltinger C, Saragovi HU, Smith RM, LeSauteur L, Shah N, DeDionisio L, Christensen L, Raible A, Jarett L, Gewirtz AM: Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J Clin Invest 95:1814, 1995
40. Geselowitz DA, Neckers LM: Analysis of oligonucleotide binding, internalization, and intracellular trafficking utilizing a novel radiolabeled crosslinker. Antisense Res Dev 2:17, 1992
41. Rosolen A, Kyle E, Chavany C, Bergan R, Kalman ET, Crouch R, Neckers L: Effect of over-expression of bacterial ribonuclease H on the utility of antisense MYC oligonucleotides in the monocytic leukemia cell line U937. Biochimie 75:79, 1993
42. McManaway ME, Marti GE, Tosato G, Liu AK, al-Nasser AA, Kiwanuka J, Magrath IT: Heterotransplantation of human Burkitt's lymphoma cell lines in athymic nude mice: tumor-host relationships. Pathobiology 61:164, 1993
43. Rosolen A, Toretsky J, Neckers L: Antisense inhibition of CHP100 C-myc expression results in reduced in vitro growth kinetics and loss of in vivo tumorigenesis. Prog Clin Biol Res 385:95, 1994
44. Harel BA, Ferris DK, Vinocour M, Holt JT, Farrar WL: Specific inhibition of c-myc protein biosynthesis using an antisense synthetic deoxy-oligonucleotide in human T lymphocytes. J Immunol 140:2431, 1988
45. Heikkila R, Schwab G, Wickstrom E, Loke SL, Pluznik DH, Watt R, Neckers LM: A c-myc antisense oligodeoxynucleotide inhibits entry into S phase but not progress from G0 to G1. Nature 328:445, 1987
46. Field JK, Spandidos DA: The role of ras and myc oncogenes in human solid tumors and their relevance in diagnosis and prognosis. Anticancer Res 10:1, 1990
47. Hunter T: Cooperation between oncogenes. Cell 64:249, 1991
48. Spencer CA, Groudine M: Control of c-myc regulation in normal and neoplastic cells. Adv Cancer Res 56:1, 1991
49. Chavany C, Connell Y, Neckers L: Contribution of sequence and phosphorothioate content to inhibition of cell growth and adhesion caused by c-myc antisense oligomers. Mol Pharmacol 48:738, 1995
50. Bergan RC, Neckers L: How do antisense oligodeoxynucleotides inhibit the growth of chronic myelogenous leukemia cells? Blood (in press)
51. Dev SB, Hofmann GA: Electrochemotherapy - A novel method of cancer treatment. Cancer Treat Rev 20:105, 1994